Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21752606 | 0.89 | GPR119 (0.59) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL16577073 | 0.86 | GPR119 (0.61) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL239883 | 0.85 | NPY2R (0.65) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL3655794 | 0.84 | NPY2R (0.58) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL18500769 | 0.83 | GPR119 (0.57) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL7494726 | 0.82 | GPR119 (0.56) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL22773246 | 0.81 | MEN1 (0.60) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL22491552 | 0.81 | MEN1 (0.60) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL27099778 | 0.81 | GPR119 (0.55) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL5763056 | 0.80 | KDM4E (0.58) | GPR119MEN1KMT2AKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436444-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10323026-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-18 | — | — | US | disclosed |
| EP-3436444-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017171100-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | WO | disclosed |
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | GPR119 2126/4885MEN1 183/4885KMT2A 1317/4885 |
| US-10323026-B2 | Heterocyclic compound | MAG, HTT, ACHE | GPR119 2126/4885MEN1 183/4885KMT2A 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.